S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NYSE:ANVS

Annovis Bio Stock Forecast, Price & News

$24.86
-0.58 (-2.28 %)
(As of 03/5/2021 05:26 PM ET)
Add
Compare
Today's Range
$20.00
Now: $24.86▼
$26.77
50-Day Range N/A
52-Week Range
$2.42
Now: $24.86▼
$35.00
Volume268,002 shs
Average Volume320,158 shs
Market Capitalization$171.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio logo

Headlines

Annovis Bio to Present at the BIO CEO & Investor Digital Conference
February 16, 2021 |  finance.yahoo.com
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
February 4, 2021 |  finance.yahoo.com
Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
February 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ANVS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.annovisbio.com
Phone610 727 3913
Employees2
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares6,906,000
Market Cap$171.68 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

1956th out of 1,972 stocks

Biotechnology Industry

122nd out of 125 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$24.86
-0.58 (-2.28 %)
(As of 03/5/2021 05:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANVS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Annovis Bio (NYSE:ANVS) Frequently Asked Questions

What stocks does MarketBeat like better than Annovis Bio?

Wall Street analysts have given Annovis Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Annovis Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Annovis Bio's key executives?

Annovis Bio's management team includes the following people:
  • Dr. Maria L. MacCecchini, Founder, CEO, Pres & Director (Age 70, Pay $120k)
  • Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 52)
  • Dr. Jeffrey L. Cummings, Chief Medical Officer & Member of Scientific Advisory Board (Age 71)
  • Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board

Who are some of Annovis Bio's key competitors?

Some companies that are related to Annovis Bio include Sigilon Therapeutics (SGTX), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Inventiva (IVA), Silence Therapeutics (SLN), Novacyt (NCYT), Landos Biopharma (LABP), Angion Biomedica (ANGN), Terns Pharmaceuticals (TERN), Pfenex (PFNX), NexImmune (NEXI), Decibel Therapeutics (DBTX), Sensei Biotherapeutics (SNSE), Burcon NutraScience (BU) and Aptose Biosciences (APS).
View all of ANVS's competitors.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), Cannabics Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Annovis Bio IPO?

(ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

What is Annovis Bio's stock symbol?

Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."

Who are Annovis Bio's major shareholders?

Annovis Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Modera Wealth Management LLC (0.63%) and Lokken Investment Group LLC (0.47%).

Which major investors are buying Annovis Bio stock?

ANVS stock was acquired by a variety of institutional investors in the last quarter, including Modera Wealth Management LLC, and Lokken Investment Group LLC.

How do I buy shares of Annovis Bio?

Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annovis Bio's stock price today?

One share of ANVS stock can currently be purchased for approximately $24.86.

How much money does Annovis Bio make?

Annovis Bio has a market capitalization of $171.68 million.

How many employees does Annovis Bio have?

Annovis Bio employs 2 workers across the globe.

What is Annovis Bio's official website?

The official website for Annovis Bio is www.annovisbio.com.

How can I contact Annovis Bio?

The company can be reached via phone at 610 727 3913.


This page was last updated on 3/5/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.